Across TCGA pan-cancer cohorts, IGFBP6 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated IGFBP6 data layer compared with 29 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher IGFBP6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGFBP6 expression acts as an unfavorable survival marker.
SKCM are the cancer types where IGFBP6 Mutation most reproducibly stratifies survival.